We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

150 hedge funds and large institutions have $1.73B invested in Ventyx Biosciences in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 30

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4.44% more ownership

Funds ownership: 85.47%89.91% (+4.4%)

3% more funds holding

Funds holding: 146150 (+4)

4% more capital invested

Capital invested by funds: $1.67B → $1.73B (+$59.7M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

77% less call options, than puts

Call options by funds: $7.2M | Put options by funds: $31.6M

Holders
150
Holders Change
+4
Holders Change %
+2.74%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
29
Increased
70
Reduced
30
Closed
25
Calls
$7.2M
Puts
$31.6M
Net Calls
-$24.4M
Net Calls Change
-$30.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$16.9M -$2.81M -81,585 -14%
VP
27
venBio Partners
California
$13.9M -$64.6M -1,874,801 -82%
VC
28
Vivo Capital
California
$13.8M -$6.2M -180,000 -30%
AG
29
Artal Group
Luxembourg
$13.4M -$4.39M -127,293 -24%
Northern Trust
30
Northern Trust
Illinois
$12.6M +$5.57M +161,613 +73%
N
31
Nuveen
North Carolina
$12M +$5.31M +153,936 +73%
IHAM
32
Integral Health Asset Management
New York
$11.5M +$2.07M +60,000 +21%
Victory Capital Management
33
Victory Capital Management
Texas
$11.1M +$481K +13,960 +4%
GC
34
GMT Capital
Georgia
$9.2M +$9.67M +280,600 New
Charles Schwab
35
Charles Schwab
California
$8.38M +$1.93M +56,121 +28%
HSBC Holdings
36
HSBC Holdings
United Kingdom
$8.23M +$8.59M +249,273 New
American Century Companies
37
American Century Companies
Missouri
$8.21M +$35.7K +1,037 +0.4%
LGM
38
Logos Global Management
California
$8.2M -$689K -20,000 -7%
Marshall Wace
39
Marshall Wace
United Kingdom
$7.87M -$6.85M -198,658 -45%
NCM
40
Nantahala Capital Management
Connecticut
$6.32M
JP Morgan Chase
41
JP Morgan Chase
New York
$6.02M -$1.73M -50,108 -21%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$5.38M +$5.65M +164,047 New
WP
43
Woodline Partners
California
$4.92M +$803K +23,286 +18%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$4.88M +$1.98M +57,396 +63%
ACP
45
Acuta Capital Partners
California
$4.83M -$2.11M -61,182 -29%
VOYA Investment Management
46
VOYA Investment Management
Georgia
$4.3M +$4.2M +121,896 +1,304%
HighTower Advisors
47
HighTower Advisors
Illinois
$4.11M +$9.34K +271 +0.2%
JFG
48
Jefferies Financial Group
New York
$4.05M -$11.1M -321,400 -72%
Deutsche Bank
49
Deutsche Bank
Germany
$3.8M +$669K +19,402 +20%
TD Asset Management
50
TD Asset Management
Ontario, Canada
$3.52M +$770K +22,351 +26%

VTYX Hedge Fund Activity: Q2 2023 in Review

150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2023, worth a combined $1.73B — up 3.6% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VTYX positions and 25 closed out — a net gain of 4 holders — while 70 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.6M. The largest seller was venBio Partners, cutting an estimated $64.6M.

  • 150 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $1.73B of Ventyx Biosciences stock for Q2 2023, up 3.6% quarter-over-quarter.
  • 29 funds opened new Ventyx Biosciences positions in Q2 2023 and 25 closed out, a net change of +4 holders.
  • The largest Ventyx Biosciences buyer in Q2 2023 was T. Rowe Price Associates, an estimated $43.6M added.
  • The largest Ventyx Biosciences seller in Q2 2023 was venBio Partners, an estimated $64.6M sold.

Based on aggregated 13F filings for Q2 2023.